PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Conditions

• Parkinson Disease

Eligibility Criteria

Sex

ALL

Age

30 Years - N/A

Healthy Volunteers

Accepted

Study Details

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Key Dates

Start date

Jul 1, 2020

Status verified

Oct 2025

Primary completion

Dec 31, 2033

Completion

Dec 31, 2033

Study Design

Enrollment

4,500 participants (estimated)

Arms

• Arm: Clinical Observation
  In PPMI Clinical up to 4,500 participants will be enrolled and followed longitudinally once identified, over the course of 5-8 years.

Primary Outcome Measure

Establish standardized protocols for acquisition, transfer and analysis of clinical, digital, imaging, biologic and genetic data that can be used by the PD research community. [ Time Frame: Baseline to 156 months ]

Central Contacts

• Cari Rainville, BS
  877-525-7764
  [email protected]

Locations (30)

Find similar trials in Birmingham, AL

Related Studies

• Genetic Studies of Lysosomal Storage Disorders
  Enrolling By Invitation · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland
• Natural History Study of Synucleinopathies
  Recruiting · NYU Langone Health · Boston, Massachusetts
• Effects of Stimulation Patterns of Deep Brain Stimulation
  Enrolling By Invitation · Duke University · Gainesville, Florida
• The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
  PHASE1/PHASE2 · Recruiting · University of Alabama at Birmingham · Birmingham, Alabama